urelumab: Clinical Trials

7 trials of urelumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 terminated, 1 completed, 1 unknown. 7 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Active not recruiting 2, Terminated 2, Completed 1, Unknown 1, Withdrawn 1
Phase 13Terminated 2, Unknown 1

Follow urelumab: new trials by email Literature Review of urelumab trials Research Report on urelumab

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Urelumab + Nivolumab - Neoplasms
Phase 1 / Phase 2UnknownClinica Universidad de Navarra, Universidad de Navarra322019-01-302019-01-03
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Nivolumab in combination with Urelumab, Nivolumab monotherapy - Urothelial Carcinoma, Bladder Cancer
Phase 2Active not recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins152017-05-162026-04-06
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
Cyclophosphamide, GVAX pancreatic cancer, Nivolumab - Pancreatic Cancer
Phase 2Active not recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins762016-03-282026-10-13
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Rituximab, Urelumab - Leukemia
Phase 2WithdrawnM.D. Anderson Cancer Center2015-07-012016-12-06
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Urelumab, Nivolumab - Advanced Solid Tumors, Advanced B-cell NHL
Phase 1 / Phase 2TerminatedBristol-Myers Squibb2322014-09-292020-10-05
Phase II, 2nd Line Melanoma - RAND Monotherapy
Anti-CD137 (4-1BB) (BMS-663513) - Melanoma
Phase 2CompletedBristol-Myers Squibb1582008-03-012015-10-12
Study of BMS-663513 in Patients With Advanced Cancer
BMS-663513 - Tumors
Phase 1 / Phase 2TerminatedBristol-Myers Squibb1152005-12-012015-10-12

Conditions studied

Neoplasms (2)  ·  Carcinoma, Transitional Cell (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Melanoma (1)  ·  Pancreatic Neoplasms (1)  ·  Recurrence (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Bristol-Myers Squibb (3)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  Clinica Universidad de Navarra, Universidad de Navarra (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (5)  ·  France (3)  ·  Canada (2)  ·  Germany (2)  ·  Spain (2)  ·  Denmark (1)  ·  Italy (1)

Top investigators

Ana De Jesus-Acosta, MD (1)  ·  Nitin Jain, MBBS (1)  ·  Noah Hahn, MD (1)

Results publications

PMID 37339979, PMID 38458639, PMID 41543348

NIH funding

2014 (1), R01CA197296 (1)